Table 2.
Detection of EGFR mutation from CTCs. The mutation detection results from CTCs isolated from total 13 patients were in 100% concordance with the corresponding results obtained from tissue biopsy sample. Notably, T790M, the acquired resistance EGFR mutation, detected at relapse (AR) of samples, but not before the treatment (BT), from two patients (LP49 and LP2) both from noninvasive blood-based CTC analysis as well as tumor biopsy.
| Patient | Sex | Age | Stage | L858R | T790M | ||
| Tissue | CTC | Tissue | CTC | ||||
| LP1 | F | 52 | IV | + | + | - | - |
| LP5 | M | 49 | IV | + | + | - | - |
| LP6 | M | 58 | IV | + | + | - | - |
| LP8 | F | 76 | IV | + | + | - | - |
| LP10 | M | 63 | IV | + | + | - | - |
| LP12 | F | 90 | IV | + | + | - | - |
| LP13 | F | 53 | IV | + | + | - | - |
| LP46 | F | 67 | IV | + | + | - | - |
| LP47 | F | 83 | IV | + | + | - | - |
| LP49 (BT) | F | 65 | IIIA | + | + | - | - |
| LP49 (AR) | F | 65 | IIIA | + | + | + | + |
| Patient | Sex | Age | Stage | 19 del | T790M | ||
| Tissue | CTC | Tissue | CTC | ||||
| LP2 (BT) | M | 53 | IV | + | + | - | - |
| LP2 (AR) | M | 53 | IV | + | + | + | + |
| LP25 | M | 74 | IV | + | + | - | - |
| LP43 | F | 59 | IV | + | + | - | - |
| 100% | 100% | ||||||